BofA upgraded bioMerieux (BMXMF) to Neutral from Underperform with a price target of EUR 115, up from EUR 90. The firm thinks competitive headwinds are reflected in estimates, that internal initiatives to improve margins are seeing momentum, and that the company can reach its 20% margin target by 2028, the analyst tells investors.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential